Protocol H8A-MC-LZAZ(a)/ADC-040-A4 Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)
The purpose of this study is to test whether an investigational drug called solanezumab, which is given by infusion through a vein, can slow the progression of memory problems associated with Alzheimer's disease.
In good general health, 65-85 years old, at risk for memory decline due to Alzheimer's.
Healthy Volunteers Needed
Duration of Participation
Chad Sorenson 503-494-7108
National Institute on Aging, Alzheimer's Therapeutic Research Institute, Eli Lilly and Co.
$25.00 for each completed clinical study visit and $25.00 for each completed infusion visit.